Greenwich LifeSciences, Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Greenwich is a clinical-stage biopharmaceutical company developing GLSI-100 (GP2 plus GM-CSF), an immunotherapy intended to prevent breast cancer recurrence. The company reported no revenue and has not commercialized a product.
Financial results and position
| Metric | Q2 2022 / June 30, 2022 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q2 2021 |
| Research and development expense | $633,250 for Q2; $2.294 million for six months | $556,534 and $838,511, respectively, in 2021 |
| General and administrative expense | $140,057 for Q2; $468,439 for six months | $196,911 and $515,540, respectively, in 2021 |
| Net loss | $746,073 for Q2; $2.716 million for six months | $749,745 and $1.347 million, respectively, in 2021 |
| Cash and total assets | $17.188 million cash; $17.199 million total assets | $27.204 million and $27.217 million, respectively, at Dec. 31, 2021 |
| Total liabilities | $229,134 | $385,172 at Dec. 31, 2021 |
| Stockholders’ equity | $16.970 million | $26.832 million at Dec. 31, 2021 |
| Cash flow | $2.480 million used in operations; $7.536 million used for share repurchases; cash decreased $10.016 million | $1.133 million used in operations and $2.273 million provided by financing in first-half 2021 |
Basic and diluted net loss per share was $0.06 for Q2 2022 and $0.21 for the first half, versus $0.06 and $0.11 in the 2021 periods. No profit or operating margin was reported because the company had no revenue.
Changes versus prior periods
- First-half R&D expense rose 174%, primarily due to higher cash compensation, clinical, and manufacturing costs; Q2 R&D expense rose 14% year over year.
- First-half net loss approximately doubled, reflecting increased operating costs; Q2 net loss was slightly lower than in Q2 2021.
- Cash declined from year-end by $10.016 million, chiefly reflecting $7.536 million of repurchases alongside operating cash use. The company repurchased about 519,828 shares through June 30.
- Liabilities were primarily accounts payable and accrued interest to the Henry M. Jackson Foundation (HJF), of which $220,845 was outstanding. The filing reports no material contractual obligations beyond employment and shareholder agreements, the GP2 license, and manufacturing and clinical-trial obligations.
Outlook, risks, and unusual items
- The company had commenced Flamingo-01, a Phase III trial of GLSI-100. Management expects significant expenses and losses to continue as it advances development and trials. It stated that additional capital will be needed for long-term operating requirements; future equity or debt financing is not assured. No specific cash runway or financial guidance was provided.
- Management described results from its completed Phase IIb study and prior GLSI-100 experience, including no observed recurrences in a specified HER2/neu 3+ subgroup after median five-year follow-up and no related serious adverse events among 146 treated patients across four trials. These are company-reported clinical observations, not a forecast of Phase III results.
- The board authorized up to $10 million of repurchases through March 31, 2023; approximately $7.536 million had been spent by June 30. The board indefinitely suspended the program on July 11, 2022.
- On June 22, the company granted options covering 1,498,128 shares at a $7.63 exercise price, with stated grant-date fair value of $9.512 million. Most of that value was unrecognized at June 30 and is subject to future vesting, including performance milestones.
- Disclosure controls were deemed ineffective at June 30 because of material weaknesses involving inadequate segregation of duties and insufficient written accounting, IT, and financial-reporting procedures. Management said it was developing a remediation plan.
- The company reported no material pending legal proceedings, no off-balance-sheet arrangements, and no material changes to previously disclosed risk factors. It relies on third-party manufacturers and has license, royalty, milestone, and patent-cost obligations under the HJF agreement.
Important facts for investors to verify
- Current cash burn, expected Phase III spending, and whether additional financing will be required and on what terms.
- Flamingo-01 enrollment, trial execution, timelines, and any subsequent clinical or regulatory updates.
- Progress and effectiveness of remediation for the disclosed internal-control material weaknesses.
- Post-quarter share repurchase activity and the effects of the option grant and other equity compensation on potential dilution.
- HJF license obligations and the scope, cost, and timing of manufacturing and clinical-trial commitments.